ストックスクリーナーアプリを入手
73.09
1.18%
-0.87
前日終値:
$73.96
開ける：
$73.93
24時間の取引高:
1.80M
Relative Volume:
0.97
時価総額：
$12.08B
収益：
$1.06B
当期純損益:
$-326.58M
株価収益率:
-34.77
EPS:
-2.1022
ネットキャッシュフロー:
$-977.73M
1週間 パフォーマンス:
-2.00%
1か月 パフォーマンス:
-1.54%
6か月 パフォーマンス:
-6.74%
1年 パフォーマンス:
+107.41%
1日の値動き範囲:
$72.30
$73.95
1週間の範囲:
$72.30
$75.85
52週間の値動き範囲:
$34.84
$86.74
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
名前
Ionis Pharmaceuticals Inc
セクター
電話
(760) 931-9200
住所
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
73.09 | 12.22B | 1.06B | -326.58M | -977.73M | -2.1022 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-21 | 開始されました | Canaccord Genuity | Buy |
| 2026-04-10 | 再開されました | Raymond James | Outperform |
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2025-10-08 | アップグレード | JP Morgan | Neutral → Overweight |
| 2025-09-26 | アップグレード | Goldman | Sell → Neutral |
| 2025-09-03 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-31 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | アップグレード | Barclays | Equal Weight → Overweight |
| 2025-04-07 | 開始されました | H.C. Wainwright | Buy |
| 2025-03-31 | 開始されました | Redburn Atlantic | Neutral |
| 2024-08-02 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | 再開されました | Jefferies | Buy |
| 2024-06-14 | アップグレード | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-10-23 | アップグレード | BofA Securities | Underperform → Neutral |
| 2023-09-29 | 開始されました | Raymond James | Strong Buy |
| 2023-07-31 | アップグレード | Citigroup | Neutral → Buy |
| 2023-06-07 | 再開されました | Piper Sandler | Overweight |
| 2023-05-04 | アップグレード | Citigroup | Sell → Neutral |
| 2023-03-21 | 開始されました | Bernstein | Underperform |
| 2022-12-21 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | 再開されました | Morgan Stanley | Overweight |
| 2022-07-18 | 再開されました | Oppenheimer | Outperform |
| 2022-03-31 | 再開されました | Piper Sandler | Overweight |
| 2022-03-01 | 開始されました | Citigroup | Sell |
| 2022-03-01 | 開始されました | Guggenheim | Buy |
| 2022-02-01 | ダウングレード | BofA Securities | Buy → Underperform |
| 2021-12-14 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | アップグレード | UBS | Sell → Neutral |
| 2021-03-01 | アップグレード | Barclays | Underweight → Equal Weight |
| 2020-12-16 | 開始されました | UBS | Sell |
| 2020-12-15 | アップグレード | Cowen | Market Perform → Outperform |
| 2020-09-14 | 再開されました | JP Morgan | Neutral |
| 2020-09-02 | 開始されました | The Benchmark Company | Hold |
| 2020-06-01 | 再開されました | Oppenheimer | Outperform |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-03-05 | 開始されました | Citigroup | Buy |
| 2019-12-13 | 開始されました | Oppenheimer | Outperform |
| 2019-11-13 | 開始されました | BofA/Merrill | Buy |
| 2019-11-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | 繰り返されました | Stifel | Hold |
| 2018-08-07 | 繰り返されました | Stifel | Hold |
| 2018-05-08 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2017-10-06 | 再開されました | Goldman | Sell |
| 2017-08-17 | 開始されました | Evercore ISI | Outperform |
| 2017-08-09 | 繰り返されました | Stifel | Hold |
| 2017-03-10 | ダウングレード | Goldman | Neutral → Sell |
| 2016-12-28 | 繰り返されました | BMO Capital Markets | Outperform |
| 2016-12-27 | 繰り返されました | Leerink Partners | Mkt Perform |
すべてを表示
Ionis Pharmaceuticals Inc (IONS) 最新ニュース
Liquidity Mapping Around (IONS) Price Events - Stock Traders Daily
IONS Reiterated by TD Cowen -- Price Target Maintained at $108 - GuruFocus
Ionis Pharmaceuticals Stock (US46120E6023): Analyst updates keep biotech in focus - AD HOC NEWS
Insider plans 8,000-share sale at IONS (NASDAQ: IONS) on 06/15/2026 - Stock Titan
5 Best Genomics Stocks to Buy According to Analysts - Insider Monkey
IONS (IONS) files Form 144 listing option-exercise shares on Nasdaq - Stock Titan
Ionis Highlights Positive Long-Term Olezarsen Data in Hypertriglyceridemia - TipRanks
Olezarsen liver fat study data highlighted by Ionis (NASDAQ: IONS) - Stock Titan
Marquis Who's Who Honors Noah Post for Expertise in Pharmaceuticals - 24-7 Press Release Newswire
Diabetic Retinopathy Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest – DelveInsight | Genentech, Ionis Pharma, AstraZeneca, Regenxbio, AbbVie, Palatin Techn, Avirmax - Barchart.com
GSK, Ionis mark late-stage trial win for chronic hepatitis B therapy - MSN
Ionis Pharmaceuticals touts $3B TRYNGOLZA opportunity, pipeline readouts at conference - MSN
Franklin Resources Inc. Has $104.53 Million Stake in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Norges Bank Invests $25.33 Million in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Amova Asset Management Americas Inc. Sells 21,021 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis Pharmaceuticals Adds Veteran Leader to Board - The Globe and Mail
Ionis Pharmaceuticals, Inc. (IONS) Presents at American Diabetes Association (ADA) 86th Scientific SessionsSlideshow (NASDAQ:IONS) 2026-06-08 - Seeking Alpha
Ionis Pharmaceuticals (NASDAQ: IONS) director Peter Reikes files baseline Form 3 - Stock Titan
Ionis Pharmaceuticals adds Ludwig Hantson to board By Investing.com - Investing.com South Africa
Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors - Lelezard
Ionis Pharmaceuticals adds Ludwig Hantson to board - Investing.com
Ionis’ ASO for ultra-rare neurological disorder awaits FDA’s decision - BioXconomy
CenterBook Partners LP Acquires Shares of 153,949 Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Capital World Investors Has $1.42 Billion Stock Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis updates time for fourth quarter and full year 2025 financial results webcast - Business Wire
Long term debt to total equity ratio of Ionis Pharmaceuticals, Inc. – XETR:ISI - TradingView
Debt to assets ratio of Ionis Pharmaceuticals, Inc. – XETR:ISI - TradingView
Price to book ratio of Ionis Pharmaceuticals, Inc. – XETR:ISI - TradingView
Ionis Pharmaceuticals (IONS) Edges Lower Amidst Sector Headwinds; Key Support Levels in FocusVanna Flow - newsline.com
ETFs Investing in Ionis Pharmaceuticals, Inc. Stocks - TradingView
Ionis Pharmaceuticals, Inc. Balance Sheet – XETR:ISI - TradingView
Ionis Pharmaceuticals, Inc. Revenue Breakdown – XETR:ISI - TradingView
Assessing Ionis Pharmaceuticals (IONS) Valuation After New Olezarsen Data Plans And Bullish Pipeline Updates - Yahoo Finance
TD Asset Management Inc Trims Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis (IONS) Q1 2026 Earnings Call Transcript - AOL.com
Arrowpoint Investment Partners Singapore Pte. Ltd. Acquires 19,554 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Key facts: Ionis licenses salanersen to Biogen; sees >$7B peak - TradingView
Why (IONS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Ionis, Alnylam, BioMarin up as Citi starts at buy on catalyst and growth outlook - MSN
Ionis Pharmaceuticals Announces New Data on Olezarsen for sHTG T - GuruFocus
Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy - Biogen
Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses - standard-journal.com
Ionis Pharmaceuticals director sells $605,360 in stock - Investing.com UK
Ionis Pharmaceuticals director sells $605,360 in stock By Investing.com - Investing.com Canada
[Form 4] IONIS PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
Ionis Pharmaceuticals Insider Sold Shares Worth $605,360, According to a Recent SEC Filing - marketscreener.com
Geode Capital Management LLC Boosts Stake in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Emergent Biosolutions (EBS) and Compass Therapeutics (CMPX) - The Globe and Mail
IONS Stock Price, Quote & Chart | IONIS PHARMACEUTICALS INC (NASDAQ:IONS) - ChartMill
IONS Reiterates by HC Wainwright & Co. -- Price Target Maintained at $125 - GuruFocus
Ionis Pharmaceuticals Inc (IONS) 財務データ
収益
当期純利益
現金流量
EPS
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):